Lucatumumab | Interleukin Related interleukin-related.com

Product Name :
Lucatumumab

Search keywords :
Lucatumumab

drugId :
null

Target Vo:
Tumor necrosis factor receptor superfamily member 5

Target Vo Short Name :
CD40

Moa_Name:
Tumor necrosis factor receptor superfamily member 5 inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Novartis Pharma Ag

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Multiple Myeloma

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
GFAP Antibody (YA416)
GPX1 Antibody
HE4 Antibody (YA889): HE4 Antibody (YA889) is an unconjugated, approximately 13-19 kDa, rabbit-derived, anti-HE4 (YA889) monoclonal antibody. HE4 Antibody (YA889) can be used for: WB, IF-Cell, IF-Tissue, IHC-P, IP, FC expriments in human, mouse background without labeling.

Author: Interleukin Related

Related Posts